Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | TACR1 | P25103 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096263 | 0.92 | SSTR4 (0.39) | SSTR4MAPTPKMSLC6A2SLC6A4 | |
| SCHEMBL16274995 | 0.91 | SSTR4 (0.42) | SSTR4CYP2D6 | |
| SCHEMBL1096141 | 0.79 | TRPM8 (0.43) | MAPTPKM | |
| SCHEMBL1097254 | 0.78 | ESR1 (0.39) | TACR1CYP2D6 | |
| SCHEMBL4067653 | 0.77 | SSTR4 (0.41) | SSTR4MAPTPKMSLC6A2SLC6A4 | |
| SCHEMBL3579316 | 0.77 | SSTR4 (0.41) | SSTR4MAPTPKMSLC6A2SLC6A4 | |
| SCHEMBL1095799 | 0.74 | MAPT (0.38) | SSTR4MAPTPKMSLC6A2SLC6A4 | |
| SCHEMBL1096262 | 0.74 | REN (0.37) | SSTR4MAPTPKMSLC6A2SLC6A4 | |
| SCHEMBL4094874 | 0.74 | SSTR4 (0.44) | SSTR4CYP2D6 | |
| SCHEMBL4106036 | 0.74 | SSTR4 (0.44) | SSTR4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | SSTR4 611/4885MAPT 4561/4885PKM 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.